LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
A recall of nearly 600 controllers used with LivaNova’s LifeSparc cardiac life support system has received its second Class I label from the FDA—this time, for a software update that aims to fix the issue that originally sparked the recall.
Jan 27 (Reuters) - The U.S. Food and Drug Administration on Friday classified the recall of LivaNova's (LIVN.O) device that controls a blood-pumping system at its most serious type, citing that their use could cause serious injuries or death.
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Verily, a subsidiary of Alphabet focused on life sciences and healthcare, today announced that the first patient has been enrolled in their collaborative UNCOVER study or “The RECOVER Sub-Study, Which Leverages Quantitative and Credible Research Tools from Verily, Will Provide Assessment Measures for Depressive Episodes.”